The life science giant’s quarterly sales of $11.01 billion increased 6% year-over-year, beating the analyst consensus estimate of $10.85 billion. Organic revenue growth was 1%.
Segment Performance Shows Strength In Bioproduction
Life Sciences Solutions sales increased 12.6% to $2.64 billion. Analytical Instruments sales were flat at $1.72 billion.
Specialty Diagnostics revenues reached $1.14 billion, and Laboratory Products and Biopharma Services sales were up 7% to $6.04 billion.
The Pharma and Biotech segment delivered mid-single-digit growth during the quarter, driven by strength in the bioproduction business, clinical research business, and Research and Safety Market channel.
In Academic and Government, revenue declined in the low single digits, driven by muted macro conditions in the U.S. and China. In Industrial and Applied, growth was flat during the quarter.
Thermo Fisher Raises FY26 Outlook After Strong Quarter
The company raised annual guidance, incorporating the positive impact of Clario and the strong first-quarter earnings performance.
Thermo Fisher Scientific raised its fiscal 2026 adjusted earnings per share guidance from $24.22-$24.80 to $24.64-$25.12 versus the consensus of $24.64.
The company increased its annual sales guidance from $46.3 billion-$47.2 billion to $47.3 billion-$48.1 billion compared to the consensus of $47.11 billion.
Thermo Fisher CEO Flags Macro Risks But Sees Resilient Demand
Marc Casper, chairman and CEO of Thermo Fisher Scientific, said, “When I think about the broader macroeconomic environment, there is added complexity given the conflict in the Middle East, and we expect this to create some modest level of inflationary pressure. Our customers remain focused on advancing their priorities, and we expect our end markets to prove resilient.”
The company’s management expressed confidence in navigating current macroeconomic challenges, including inflation, by leveraging its PPI business system.
TMO Price Action: Thermo Fisher Scientific shares were down 10.45% at $460.26 at the time of publication on Thursday, according to Benzinga Pro data.
Image via Shutterstock
Market News and Data brought to you by Benzinga APIs
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.